Publication: Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome.
Accepted Date
2014-02-10
Issued Date
2014
Resource Type
Language
eng
ISSN
1758-5996 (electronic)
Rights
Mahidol University
Rights Holder(s)
PubMed Central
Bibliographic Citation
Thanakun S, Watanabe H, Thaweboon S, Izumi Y. Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome. Diabetol Metab Syndr. 2014; 6: 19.
Suggested Citation
Supanee Thanakun, สุพานี ธนาคุณ, Hisashi Watanabe, Sroisiri Thaweboon, สร้อยศิริ ทวีบูรณ์, Yuichi Izumi Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome.. Thanakun S, Watanabe H, Thaweboon S, Izumi Y. Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome. Diabetol Metab Syndr. 2014; 6: 19.. doi:10.1186/1758-5996-6-19 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/938
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome.
Corresponding Author(s)
Abstract
Background
The relationship of saliva with plasma protein levels makes saliva an attractive diagnostic tool. Plasma levels of adiponectin and leptin in healthy individuals or diabetes mellitus patients have been previously reported. Nevertheless, salivary levels of these adipocytokines in patients with metabolic syndrome (MS) have never been investigated. This study was aimed to determine adiponectin and leptin levels in saliva and plasma from patients with metabolic syndrome, and evaluate any correlation of these levels with MS.
Methods
Forty-six healthy and 82 MS patients were enrolled. Demographic data and blood biochemistries were recorded. Saliva and plasma adiponectin and leptin levels were analyzed by enzyme-linked immunosorbent assay (ELISA).
Results
Adiponectin and leptin were higher in plasma than in saliva (p < .001). Plasma adiponectin was decreased and plasma leptin increased in patients with MS (p < .001). Salivary adiponectin and salivary leptin were not different between healthy subjects and MS patients (p = .619 and p = .523). Correlation between salivary and plasma adiponectin showed significant association (r = .211, p = .018) while salivary and plasma leptin had no correlation (r = -.161, p = .069). Significant correlation was observed between the salivary adiponectin/salivary leptin ratio and plasma adiponectin (r = .371, p < .001), but not with any component of MS. Increased triglyceride and waist circumference were associated with risk of having a low level of plasma adiponectin (OR = 1.009; 95% CI 1.002–1.015 and OR = 1.125; 95% CI 1.029–1.230). For leptin, body mass index and high-density lipoprotein cholesterol (HDL-C) were associated with a high level of plasma leptin (OR = 1.621; 95% CI 1.212–2.168 and OR = .966; 95% CI .938–.996). The OR for MS as predicted by plasma adiponectin was .928 (95% CI .881-.977).
Conclusions
This study showed that salivary adiponectin and leptin do not correlate with MS. Although correlation between salivary and plasma adiponectin was observed, no association with MS was observed. Only plasma adiponectin may be useful for the prediction of MS.